X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ELDER PHARMA PLETHICO PHARMA/
ELDER PHARMA
 
P/E (TTM) x -1.1 -0.2 - View Chart
P/BV x 0.0 0.1 16.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ELDER PHARMA
Jun-14
PLETHICO PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs395380 103.9%   
Low Rs31188 16.6%   
Sales per share (Unadj.) Rs604.4491.2 123.0%  
Earnings per share (Unadj.) Rs32.5-3.2 -1,020.8%  
Cash flow per share (Unadj.) Rs51.314.4 356.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6376.5 125.8%  
Shares outstanding (eoy) m34.0820.54 165.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.6 61.0%   
Avg P/E ratio x6.6-89.3 -7.4%  
P/CF ratio (eoy) x4.219.7 21.1%  
Price / Book Value ratio x0.50.8 59.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2625,833 124.5%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5962,179 73.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59810,089 204.2%  
Other income Rs m386257 150.6%   
Total revenues Rs m20,98410,346 202.8%   
Gross profit Rs m2,818-792 -355.8%  
Depreciation Rs m642361 177.8%   
Interest Rs m1,5932,756 57.8%   
Profit before tax Rs m969-3,653 -26.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m-138125 -110.6%   
Profit after tax Rs m1,107-65 -1,693.8%  
Gross profit margin %13.7-7.8 -174.3%  
Effective tax rate %-14.3-3.4 417.0%   
Net profit margin %5.4-0.6 -829.6%  
BALANCE SHEET DATA
Current assets Rs m18,8779,240 204.3%   
Current liabilities Rs m11,8969,998 119.0%   
Net working cap to sales %33.9-7.5 -451.3%  
Current ratio x1.60.9 171.7%  
Inventory Days Days3646 77.6%  
Debtors Days Days19860 330.0%  
Net fixed assets Rs m9,86110,124 97.4%   
Share capital Rs m341206 165.6%   
"Free" reserves Rs m12,3315,582 220.9%   
Net worth Rs m16,1397,734 208.7%   
Long term debt Rs m4,7064,889 96.3%   
Total assets Rs m33,14622,882 144.9%  
Interest coverage x1.6-0.3 -494.3%   
Debt to equity ratio x0.30.6 46.1%  
Sales to assets ratio x0.60.4 140.9%   
Return on assets %8.111.8 69.3%  
Return on equity %6.9-0.8 -811.6%  
Return on capital %12.322.3 55.1%  
Exports to sales %21.43.0 703.3%   
Imports to sales %15.20.4 3,563.9%   
Exports (fob) Rs m4,402307 1,435.9%   
Imports (cif) Rs m3,13643 7,276.1%   
Fx inflow Rs m4,402307 1,435.9%   
Fx outflow Rs m3,184125 2,541.0%   
Net fx Rs m1,219181 672.1%   
CASH FLOW
From Operations Rs m2,43711,754 20.7%  
From Investments Rs m-6,265-561 1,117.7%  
From Financial Activity Rs m2,490-6,762 -36.8%  
Net Cashflow Rs m-1,3374,432 -30.2%  

Share Holding

Indian Promoters % 82.7 39.6 208.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 7.5 57.3%  
FIIs % 5.5 16.8 32.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 36.1 20.8%  
Shareholders   10,665 16,479 64.7%  
Pledged promoter(s) holding % 85.7 77.6 110.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS